about us
the Kode Group
Kode Biotech is the holder and parent of companies that license Kode Technology for different sectors and uses. The group also includes GlycoNZ, which supplies a broad range of glycoconjugate research probes, including FSL constructs.
Kode Group structure: multiple companies, one body of science
Kode Group companies: who does what
Kode Biotech
Owns Kode Technology and its intellectual property. Designs and makes FSL constructs, and sells them worldwide through GlycoNZ.
GlycoNZ
Sells research FSL constructs and glycoconjugates through glyconz.com and Merck MilliporeSigma.
Kode Biotech Materials
Supplies FSL constructs at large scale, quality-assured, direct to pharmaceutical companies.
Kode Veterinary Sciences
Kode Agalimmune
Develops AGI-134, a Gen 2 KIE, for human cancer, and holds the alpha(Gal)OV-IO oncolytic virus asset.
KodeRx
Develops K5K, a Gen 3 KIE, for human cancer, with a focus on affordable and accessible products.
New applications
Kode Biotech develops each major application of Kode Technology through its own company. Further spin-out companies may be formed as new applications mature.
Kode Technology resources, including the Technical Manual and Stephen Henry's DSc thesis, are free on the Downloads page. The research, manufacturing, and sales and distribution partners the group works with are on the Our Partners page.
meet our peopleWork with us: partner with kode
Licensing, research collaboration and custom FSL constructs.